Aldeyra plummets, says FDA may decline to approve its eye disease drug

Aldeyra Therapeutics

16/10/2023 14:57

** Shares of drug developer Aldeyra Therapeutics  ALDX.O 
fall ~64.3% to $1.93
    ** Co says the U.S. FDA found insufficient data supporting
ALDX's experimental dry eye disease treatment 
    ** Says the health regulator may decline to approve the drug
after it said ALDX needs to conduct an additional clinical trial
to satisfy efficacy requirements 
    ** Including session moves, shares down ~76% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))